Cardiovascular and renal outcomes with empagliflozin in heart failure


From the Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas (MP); Imperial College (MP) and the Department of Medical Statistics, London School of Hygiene and Tropical Medicine (SJP), London, BHF Glasgow Cardiovascular Research Center, University of Glasgow, Glasgow (NS), and the Department of Cardiovascular Sciences, University of Leicester and the Biomedical Research Center of the National Institute for Health Research, Glenfield Hospital, Leicester (IS) – all in the UK; the Department of Cardiology and the Berlin Institute of Health Center for Regenerative Therapies, German Cardiovascular Research Center Partner Site Berlin, Charité Universitätsmedizin, Berlin (SDA), Boehringer Ingelheim International, Ingelheim (M. Brueckmann, WJ), Faculty of Medicine Mannheim, University of Heidelberg, Mannheim (M. Brueckmann), Boehringer Ingelheim Pharma, Biberach (CZ), Klinik für Innere Medizin III, University of Saarland, Homburg – Saar (M. Böhm), ​​and the Department of Medicine, Würzburg University Hospital, Würzburg (CW) – all in Germany; the Department of Medicine, University of Mississippi School of Medicine, Jackson (JB); Athens National and Kapodistrian University School of Medicine, Athens Attikon University Hospital, Athens (GF); Washington DC Veterans Medical Center, Washington DC (PC); the Division of Cardiology, Harvard Medical School and Massachusetts General Hospital, Boston (JJ); the Division of Cardiac Surgery, St. Michael’s Hospital, University of Toronto, Toronto (SV), Boehringer Ingelheim Canada, Burlington, ON (KK), and the Division of Cardiology, McGill University and Health Center, Montreal (NG) – all in Canada; the Department of Cardiovascular Medicine, Kyushu University, Higashi-ku, Fukuoka, Japan (HT); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (J. Schnee, DC); Institute of Cardiology, School of Medicine of the University of São Paulo, São Paulo (EB); Department of Medicine, Seoul National University, Seoul, South Korea (D.-JC); the Department of Cardiology, Max Super Specialty Hospital, Saket, New Delhi, India (VC); the Department of Clinical Cardiology, National Institute of Cardiology, Mexico City (CE); the Department of Cardiology, Gasthuisberg University Hospital of Louvain, Louvain, Belgium (SJ); Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (JZ); the cardiology department, university hospital, Santiago de Compostela, Spain (JRGJ); the Department of Cardiology, Cedars – Sinai Medical Center, Los Angeles (SK); Maastricht Heart and Vascular Center, Maastricht, The Netherlands (HPB-LR); the Heart and Vascular Center, Semmelweis University, Budapest, Hungary (BM); Victorian Heart Institute and Monash University, Melbourne, VIC, Australia (SJN); Fleni El Cruce Institute and Hospital – Nestor Kirchner, Buenos Aires (SP); the Department of Medicine at Wayne State and Central Michigan Universities, Detroit (IP); the Center for Heart Disease, Wrocław Medical University, Wrocław, Poland (PP); the Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo (MS), and the Department of Clinical and Experimental Medicine, University of Pisa, Pisa (ST) – both in Italy; the Department of Cardiology, CHU Jean Minjoz, Besançon (M.-FS), and the University of Lorraine, INSERM Investigation Network Initiative – Cardiovascular and Renal Clinical Trials, Regional University Hospital, Nancy (FZ) – both in France; and internal cardiology, Brno University Hospital, Brno, Czech Republic (J. Spinar).

Direct reprint requests to Dr. Packer, Baylor Heart and Vascular Institute, 621 N. Hall St., Dallas, TX 75226, or [email protected].


Please enter your comment!
Please enter your name here